Stroke, Vol 14, 15-22, Copyright © 1983 by American Heart Association
PS Sorensen, H Pedersen, J Marquardsen, H Petersson, A Heltberg, N Simonsen, O Munck and LA Andersen
Two hundred and three patients, 148 males and 55 females, who during the
last month before admission had experienced at least one reversible
cerebral ischemic attack of less than 72 hours duration, were randomly
assigned to treatment with either acetylsalicylic acid (ASA) 1000 mg daily
(101 patients) or placebo (102 patients). The average follow-up period was
25 months. The two treatment groups were comparable with respect to age,
sex, associated diseases, risk factors, number and duration of cerebral
ischemic attacks. No statistically significant differences were found
between the treatment groups as to the primary end point: stroke or death
(ASA group 20.8%, placebo group 16.7%). Occurrence of transient ischemic
attacks during the treatment period was not reduced by ASA treatment,
whereas there was a trend suggesting fewer myocardial infarctions in the
ASA group (5.9%) than in the placebo group (13.7%). The difference,
however, was not statistically significant (p = 0.10). We were thus unable
to demonstrate any favorable influence of ASA 1000 mg daily in patients
with reversible ischemic attacks. This study does not, of course, prove
that ASA treatment is ineffective in stroke prevention.
ARTICLES
Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks. A Danish cooperative study
This article has been cited by other articles:
 |
|
 |
|
  V. Thijs, R. Lemmens, and S. Fieuws Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke Eur. Heart J., May 1, 2008; 29(9): 1086 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. O'Donnell, G. J. Hankey, and J. W. Eikelboom Antiplatelet Therapy for Secondary Prevention of Noncardioembolic Ischemic Stroke: A Critical Review Stroke, May 1, 2008; 39(5): 1638 - 1646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Vorchheimer and R. Becker Platelets in Atherothrombosis Mayo Clin. Proc., January 1, 2006; 81(1): 59 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Touze, O. Varenne, G. Chatellier, S. Peyrard, P. M. Rothwell, and J.-L. Mas Risk of Myocardial Infarction and Vascular Death After Transient Ischemic Attack and Ischemic Stroke: A Systematic Review and Meta-Analysis Stroke, December 1, 2005; 36(12): 2748 - 2755. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Gorelick and S. M. Weisman Risk of Hemorrhagic Stroke With Aspirin Use: An Update Stroke, August 1, 2005; 36(8): 1801 - 1807. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tran and S. S. Anand Oral Antiplatelet Therapy in Cerebrovascular Disease, Coronary Artery Disease, and Peripheral Arterial Disease JAMA, October 20, 2004; 292(15): 1867 - 1874. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Eliasziw, J. Kennedy, M. D. Hill, A. M. Buchan, and H. J.M. Barnett Early risk of stroke after a transient ischemic attack in patients with internal carotid artery disease Can. Med. Assoc. J., March 30, 2004; 170(7): 1105 - 1109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Flossmann and P. M. Rothwell Prognosis of vertebrobasilar transient ischaemic attack and minor stroke Brain, September 1, 2003; 126(9): 1940 - 1954. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. H. Awtry and J. Loscalzo Aspirin Circulation, March 14, 2000; 101(10): 1206 - 1218. [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Johnson, S. F. Lanes, C. E. Wentworth III, M. H. Satterfield, B. L. Abebe, and L. W. Dicker A Metaregression Analysis of the Dose-Response Effect of Aspirin on Stroke Arch Intern Med, June 14, 1999; 159(11): 1248 - 1253. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G Thrift, J. J McNeil, A. Forbes, and G. A Donnan Risk of primary intracerebral haemorrhage associated with aspirin and non-steroidal anti-inflammatory drugs: case-control study BMJ, March 20, 1999; 318(7186): 759 - 764. [Abstract] [Full Text]
|
|
|
|
|
|
J. He, P. K. Whelton, B. Vu, and M. J. Klag Aspirin and Risk of Hemorrhagic Stroke: A Meta-analysis of Randomized Controlled Trials JAMA, December 9, 1998; 280(22): 1930 - 1935. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Eccles, N. Freemantle, J. Mason, and t. N. o. E. A. G. D. Group North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care BMJ, April 25, 1998; 316(7140): 1303 - 1309. [Full Text]
|
|
|
|
 |
|
 S. Maruyama, S. Uchiyama, H. Tohgi, S. Hirai, Y. Ikeda, Y. Shinohara, T. Matsuda, M. Fujishima, and M. Kameyama A Randomized Trial of E5510 versus Aspirin in Patients with Transient Ischemic Attacks: The Japanese E5510 TIA Study-1 (JETS-1) Group Angiology, November 1, 1995; 46(11): 999 - 1008. [Abstract] [PDF]
|
|
|
|
|
|
J. Weil, D. Colin-Jones, M. Langman, D. Lawson, R. Logan, M. Murphy, M. Rawlins, M. Vessey, and P. Wainwright Prophylactic aspirin and risk of peptic ulcer bleeding BMJ, April 1, 1995; 310(6983): 827 - 830. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. B. Gorelick Stroke Prevention Arch Neurol, April 1, 1995; 52(4): 347 - 355. [Abstract] [PDF]
|
|
|
|
 |
|
 H. J.M. Barnett, M. Eliasziw, and H. E. Meldrum Drugs and Surgery in the Prevention of Ischemic Stroke N. Engl. J. Med., January 26, 1995; 332(4): 238 - 248. [Full Text] [PDF]
|
|
|
|
|
|
Antiplatelet Trialists Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ, January 8, 1994; 308(6921): 81 - 106. [Abstract] [Full Text]
|
|
|
|
|
|
J. L. Wilterdink and J. D. Easton Vascular Event Rates in Patients With Atherosclerotic Cerebrovascular Disease Arch Neurol, August 1, 1992; 49(8): 857 - 863. [Abstract] [PDF]
|
|
|
|
 |
|
 J. F. Rothrock and R. G. Hart Antithrombotic Therapy in Cerebrovascular Disease Ann Intern Med, December 1, 1991; 115(11): 885 - 895. [Abstract] [PDF]
|
|
|
|
 |
|
 B. Aspey and M. Harrison Sex differences in the antithrombotic effectiveness of aspirin Vascular Medicine, September 1, 1990; 1(2): 113 - 119. [PDF]
|
|
|
|
|
|
J. Marshall Controlled Clinical Trials in Cerebrovascular Disease: A Misused Tool Arch Neurol, April 1, 1990; 47(4): 444 - 445. [Abstract] [PDF]
|
|
|
|
 |
|
 G. P. Clagett Antithrombotic Drugs and Vascular Surgery Perspectives in Vascular Surgery and Endovascular Therapy, January 1, 1990; 3(2): 79 - 102. [PDF]
|
|
|
|
|
|
J. I. Ausman, C. E. Shrontz, J. E. Pearce, F. G. Diaz, and J. L Crecelius Vertebrobasilar Insufficiency: A Review Arch Neurol, August 1, 1985; 42(8): 803 - 808. [Abstract] [PDF]
|
|